SCIENCE SOURCED WORLDWIDE
Omilancor is a novel gut-restricted small molecule investigational drug that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway impacting the gastrointestinal tract. LANCL2 plays an important role in the immunoregulatory process. By activating the LANCL2 pathway and modulating the interactions between immunological and metabolic signals in immune cells, omilancor is designed to create a favorable regulatory microenvironment in the gut, decreasing the production of key inflammatory mediators and increasing anti-inflammatory markers in regulatory T cells (Treg) within the site of inflammation.
Phase 2
Phase 3
Phase 2
Phase 3
Inflammatory bowel disease (IBD) is a chronic autoimmune inflammatory condition that primarily affects the intestines and colon. It is believed to be caused by a mix of genetic and environmental factors in which immune response is triggered from various potential stimulants such as bacteria crossing the intestinal lumen barrier. IBD produces a range of signs and symptoms ranging from mild to severe that negatively impact quality of life. The most common symptoms include abdominal pain, diarrhea, weight loss, and anemia. IBD can be further classified into ulcerative colitis (UC), which affects the large intestine (colon) and rectum, and Crohn’s disease, which can affect any part of the gastrointestinal tract but most commonly affects the small bowel. IBD can lead to severe adverse outcomes including colectomy, disability and colorectal cancer.
In China, IBD is estimated to affect more than 590,000 patients, with incidence expected to increase significantly over the coming decade. UC is more prevalent in ages 20-49 while CD is more prevalent in ages 18-35.
LianBio plans to develop omilancor in China for the treatment of UC and CD by enrolling patients in our territories in future global registrational trials conducted by Landos.
NX-13 is a first-in-class, gut-restricted, small molecule therapeutic candidate for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). NX-13 targets NLRX1, a mitochondria-associated receptor with the ability to modulate immune responses. By activating the NLRX1 pathway, NX-13 increases autophagy and oxidative phosphorylation in immune cells, while decreasing differentiation of effector CD4+ T cells, reactive oxygen species, inflammasome formation and production of inflammatory cytokines.
Phase 1
Phase 3
Phase 1
Phase 3
Inflammatory bowel disease (IBD) is a chronic autoimmune inflammatory condition that primarily affects the intestines and colon. It is believed to be caused by a mix of genetic and environmental factors in which immune response is triggered from various potential stimulants such as bacteria crossing the intestinal lumen barrier. IBD produces a range of signs and symptoms ranging from mild to severe that negatively impact quality of life. The most common symptoms include abdominal pain, diarrhea, weight loss, and anemia. IBD can be further classified into ulcerative colitis (UC), which affects the large intestine (colon) and rectum, and Crohn’s disease, which can affect any part of the gastrointestinal tract but most commonly affects the small bowel. IBD can lead to severe adverse outcomes including colectomy, disability and colorectal cancer.
In China, IBD is estimated to affect more than 590,000 patients, with incidence expected to increase significantly over the coming decade. UC is more prevalent in ages 20-49 while CD is more prevalent in ages 18-35.
LianBio plans to develop NX-13 in China for the treatment of UC and CD by enrolling patients in our territories in future global registrational trials conducted by Landos.
LYR-210 is an investigational anti-inflammatory implantable drug matrix that is designed to consistently and locally elute mometasone furoate (“MF”) to inflamed mucosal sinus tissue for up to six months with a single administration to treat chronic rhinosinusitis (CRS). LYR-210 is designed as a non-invasive alternative to sinus surgery for those who have failed standard medical management.
Phase 2
Phase 3
Phase 2
Phase 3
Chronic rhinosinusitus (“CRS”) is an inflammatory disease of the paranasal sinuses in which the mucosa lining the sinuses become swollen and inflamed, leading to debilitating symptoms and significant morbidities. Inflammation may be caused by infections, allergies or environmental factors, as well as structural issues such as blockages of an ostium. If the sinus drainage pathways become blocked, normal mucus drainage is prevented and damage to ciliary function may occur. The four primary symptoms of CRS are nasal obstruction and congestion, facial pain and pressure, nasal discharge and loss of smell. There are two main types of CRS – CRS with nasal polyps, which are teardrop-shaped benign masses arising from the mucosa, and CRS without nasal polyps, with the non-polyp form representing approximately 70% to 90% of CRS patients. Patients with polyps develop non-cancerous polyps on the chronically inflamed surfaces, but both subgroups typically share the same symptoms and level of severity. Currently, most therapies target CRS patients with polyps and there are no approved treatments for CRS patients without polyps who have failed medical therapy, creating a vast untapped market opportunity for a more effective treatment solution.
Chronic rhinosinusitus (CRS) constitutes a substantial disease burden in Asia, with 88 million cases in Chinese adults ages 18-74 alone. Current treatments aim to manage symptoms through medical management and invasive surgical intervention techniques. It is estimated that at least 40% of patients in China with CRS who are seen by ear, nose and throat physicians remain symptomatic.
LianBio plans to join the future global development program for LYR-210 for the treatment of CRS by enrolling patients in China.